HomeCompareNPPNY vs CHD

NPPNY vs CHD: Dividend Comparison 2026

NPPNY yields 2.84% · CHD yields 1.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NPPNY wins by $132.0K in total portfolio value
10 years
NPPNY
NPPNY
● Live price
2.84%
Share price
$7.40
Annual div
$0.21
5Y div CAGR
47.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$158.3K
Annual income
$65,881.22
Full NPPNY calculator →
CHD
CHD
● Live price
1.27%
Share price
$93.91
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,292.51
Full CHD calculator →

Portfolio growth — NPPNY vs CHD

📍 NPPNY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNPPNYCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NPPNY + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NPPNY pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NPPNY
Annual income on $10K today (after 15% tax)
$241.22/yr
After 10yr DRIP, annual income (after tax)
$55,999.04/yr
CHD
Annual income on $10K today (after 15% tax)
$107.94/yr
After 10yr DRIP, annual income (after tax)
$1,098.63/yr
At 15% tax rate, NPPNY beats the other by $54,900.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NPPNY + CHD for your $10,000?

NPPNY: 50%CHD: 50%
100% CHD50/50100% NPPNY
Portfolio after 10yr
$92.3K
Annual income
$33,586.86/yr
Blended yield
36.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

NPPNY
No analyst data
Altman Z
6.7
Piotroski
5/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+4.8% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NPPNY buys
0
CHD buys
0
No recent congressional trades found for NPPNY or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNPPNYCHD
Forward yield2.84%1.27%
Annual dividend / share$0.21$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR47.7%23.1%
Portfolio after 10y$158.3K$26.4K
Annual income after 10y$65,881.22$1,292.51
Total dividends collected$128.1K$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: NPPNY vs CHD ($10,000, DRIP)

YearNPPNY PortfolioNPPNY Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$11,119$419.15$10,856$156.32+$263.00NPPNY
2$12,541$643.33$11,811$195.24+$730.00NPPNY
3$14,420$1,001.58$12,883$244.38+$1.5KNPPNY
4$17,019$1,589.76$14,091$306.64+$2.9KNPPNY
5$20,801$2,590.00$15,463$385.88+$5.3KNPPNY
6$26,626$4,369.50$17,033$487.17+$9.6KNPPNY
7$36,211$7,720.76$18,843$617.36+$17.4KNPPNY
8$53,240$14,493.90$20,947$785.72+$32.3KNPPNY
9$86,382$29,415.55$23,419$1,004.91+$63.0KNPPNY
10$158,310$65,881.22$26,350$1,292.51+$132.0KNPPNY

NPPNY vs CHD: Complete Analysis 2026

NPPNYStock

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.

Full NPPNY Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this NPPNY vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NPPNY vs SCHDNPPNY vs JEPINPPNY vs ONPPNY vs KONPPNY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.